ReVivo Medical is developing the next generation of implants for spinal surgery.
Proud to be working with these trusted institutions:
16
PATENTS ISSUED
Current US and international patients issued as of Sep 2023.
38
PATIENTS IMPLANTED
Patients implanted in our ongoing clinical trial.
$5.4M
CAPITAL RAISED
$5.4 million raised in angel investor funding.
Flagship Products
CEM-Plate Anterior Cervical Plating System®
The CEM-Plate® Anterior Cervical Plating System has unique features which include an integrated Zero-Step anti-backout, keyhole slots designed to allow for more efficient workflow in the operating room, and a monolithic design which eliminates assembly costs.
CEM-Cage Cervical Interbody System®
The CEM-Cage® Cervical Interbody System is manufactured from titanium and has features which are designed to enhanced visualization during surgery and allow placement of more bone graft.
Surgical Technique
Anterior cervical discectomy and fusion (ACDF) procedures have been performed for more than 50 years for patients with neck pain who fail conservative care. Our unique implants and instruments have features that allow for an efficient workflow during surgery.
Disclaimer: ReVivo Medical’s CEM-Cage® and CEM-Plate® are investigational only and not for sale or use in the United States.
First-in-Human-Use Clinical Trial
ReVivo Medical is currently engaged in an FDA sanctioned first-in-human-use clinical trial to evaluate the safety and efficacy of the CEM-Plate® and CEM-Cage®.
Created with patient outcomes in mind.
We aim for faster bone formation and fewer complications so patients can quickly return to life, work, and the things they love.
Engineered to eliminate common surgical procedure complications.
With enhanced intra-operative visualization, our implants are engineered to optimize placement and reduce complications.
Designed for an efficient workflow in the operating room.
Our uniquely designed implants and instruments streamline the surgical procedure with fewer steps in the operation room.
Designed to eliminate assembly costs.
Our smart monolithic design simplifies the manufacturing process and results in a zero-assembly implant.
About the Company
ReVivo Medical’s founders have decades of experience performing complex spine surgical procedures and conducting award-winning research. The company was founded to develop next generation spinal implants with the goal of improving patient outcomes, simplifying the workflow in the operating room, and reducing the number of components in implants. The company is currently conducting an FDA sanctioned first-in-human use clinical trial to evaluate its first two products. Once the products are market-ready, ReVivo’s aim is to sell or license its product portfolio to a strategic partner.
Meet the executive team.
With decades of experience, ReVivo’s leadership team has the skill set to develop and commercialize medical devices for the spine.
Scientific Articles
Decades of research in spine biomechanics and bone formation motivate the unique designs of ReVivo's implants.
ReVivo Medical’s anterior cervical plate accelerates bone formation and interbody fusion in a pre-clinical model.
A more compliant anterior cervical plate promotes load-sharing and less posterior element strain in vitro.
Load-sharing is more consistent & load-reversal is eliminated with a lower stiffness anterior cervical plate in vivo.
Frequently Asked Questions
Are the ReVivo products motion preservation?
No. The CEM-Plate® Anterior Plating System and CEM-Cage® Cervical Interbody System are fusion devices. If cleared by the FDA, they will be indicated for anterior cervical interbody fusion procedures and are intended to provide stability after discectomy and decompression.
Is there a unique anti-backout mechanism in the CEM-Plate®?
Yes. There is a patented “Zero Step” anti-backout mechanism integrated into the CEM-Plate®. As a screw is driven into the plate, the head of screw passes an integrated lip that prevents screw backout.
What is ReVivo’s value proposition?
In the estimated $2.5B cervical fusion implant market, current products are commodities with few distinguishing features. ReVivo Medical’s philosophy is to develop products which promote better outcomes for the patient, are easier for the surgeon to use, and are cost-competitive to manufacture. The CEM-Cage® and CEM-Plate® are ReVivo’s flagship products. They are both currently under investigation.
Why should a fusion implant be less stiff?
ReVivo Medical’s philosophy is promotion of load-sharing. Research in orthopaedics has shown that implants with high stiffness can stress-shield and impede newly forming bone. Implants with lower stiffness can load-share and enhance bone formation.
Are there fewer steps in the ACDF workflow with the ReVivo plate and cage?
Yes. The patented “Screws-First” technique allows the surgeon to use the screws for distraction using ReVivo’s low profile distractor, eliminating the need for dedicated distraction pins.
When will ReVivo be able to go to market?
In the United States, all medical products must be authorized by the FDA to go to market. ReVivo’s first two products, the CEM-Cage® and CEM-Plate®, have undergone laboratory testing and pre-clinical testing to satisfy the FDA’s requirements. The two products are currently being investigated in a first-in-human-use clinical trial. Once the trial is complete, ReVivo will submit the data to the FDA in an application for clearance.
Is there any pre-clinical evidence of efficacy of the ReVivo devices?
Yes. ReVivo Medical has conducted extensive pre-clinical testing of the CEM-Cage® and CEM-Plate®. The results from an in vivo pre-clinical efficacy study were published in The Spine Journal and show that the CEM-Plate® promoted faster better bone formation in a pre-clinical model.
Is there anything unique about how the ReVivo implants are manufactured?
Yes. The CEM-Cage® and CEM-Plate® are both monolithic – each is made of a single component with no assembly. Both implants are made of Ti6Al4V, the same material as most other commercially available titanium implants.
Will the competitors be able to make look alike products?
ReVivo has 16 issued patents in the United States, Europe, and Canada to protect the CEM-Plate®, the CEM-Cage®, other pipeline products, and the associated instruments. The patents protect the designs of the devices and also protect features and methods related to their design and use. Additional patents are pending.
Connect with us.
Click the link below to request additional information or start a conversation.